-
公开(公告)号：US20120156724A1
公开(公告)日：2012-06-21
申请号：US13329658
申请日：2011-12-19
Applicant: Yasufumi Kikuchi , Shinsuke Uno , Yasuko Kinoshita , Shigeyuki Iijima , Naoshi Fukushima , Masayuki Tsuchiya
Inventor： Yasufumi Kikuchi , Shinsuke Uno , Yasuko Kinoshita , Shigeyuki Iijima , Naoshi Fukushima , Masayuki Tsuchiya
CPC classification number: C07K16/2803 , C07K2317/24 , C07K2317/50 , C07K2317/73
Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.
Abstract translation: 本发明涉及与CD47结合的人源化抗体; 结合人CD47的双抗体，其特征在于二糖键存在于形成双抗体的片段之间; 编码任何一种所述抗体的基因; 含有所述基因的载体; 含有所述载体的宿主细胞; 制备抗体的方法包括培养所述宿主细胞的步骤; 和包含所述抗体的血液病症治疗剂。
-
2.发明申请公开(公告)号：US20070212359A1
公开(公告)日：2007-09-13
申请号：US11547534
申请日：2005-03-31
Applicant: Hiroyuki Aburatani , Yoshitaka Hippo , Akira Watanabe , Yukio Ito , Hirotaka Ito , Shin-ichi Funahashi , Masashi Fukayama , Masahiro Arai , Toshihiko Ohtomo , Yasuko Kinoshita
Inventor： Hiroyuki Aburatani , Yoshitaka Hippo , Akira Watanabe , Yukio Ito , Hirotaka Ito , Shin-ichi Funahashi , Masashi Fukayama , Masahiro Arai , Toshihiko Ohtomo , Yasuko Kinoshita
IPC: A61K39/395 , G01N33/574 , C07K16/30
CPC classification number: G01N33/57438 , C07K2317/732 , C07K2317/734 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57446 , G01N33/576
Abstract: A method for diagnosing cancer comprising detecting ROBO1 protein is disclosed. In addition, a method for treating a disease caused by abnormal cell growth comprising administrating an antibody that binds to ROBO1, as well as a pharmaceutical composition, a cell growth inhibitor and an anticancer agent comprising an antibody that binds to ROBO1 as an active ingredient are disclosed. Further, a method for inducing cell damages in a ROBO1 expressing cell and a method for inhibiting the growth of a ROBO1 expressing cell by bringing a ROBO1 expressing cell into contact with an antibody that binds to ROBO1, are disclosed. Furthermore, a method for monitoring progression of hepatitis by detecting ROBO1 protein is disclosed.
Abstract translation: 公开了一种诊断癌症的方法，包括检测ROBO1蛋白。 另外，用于治疗由异常细胞生长引起的疾病的方法包括施用与ROBO1结合的抗体，以及药物组合物，细胞生长抑制剂和抗癌剂，其包含结合ROBO1作为有效成分的抗体的方法， 披露 此外，公开了通过使ROBO1表达细胞与与ROBO1结合的抗体接触来抑制ROBO1表达细胞中的细胞损伤的方法和抑制ROBO1表达细胞的生长的方法。 此外，公开了通过检测ROBO1蛋白来监测肝炎进展的方法。
-
公开(公告)号：US08940488B2
公开(公告)日：2015-01-27
申请号：US11547534
申请日：2005-03-31
Applicant: Hiroyuki Aburatani , Yoshitaka Hippo , Akira Watanabe , Masashi Fukayama , Yukio Ito , Masahiro Arai , Hirotaka Ito , Toshihiko Ohtomo , Shin-ichi Funahshi , Yasuko Kinoshita
Inventor： Hiroyuki Aburatani , Yoshitaka Hippo , Akira Watanabe , Masashi Fukayama , Yukio Ito , Masahiro Arai , Hirotaka Ito , Toshihiko Ohtomo , Shin-ichi Funahshi , Yasuko Kinoshita
IPC: G01N33/53 , G01N33/574 , G01N33/576
CPC classification number: G01N33/57438 , C07K2317/732 , C07K2317/734 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57446 , G01N33/576
Abstract: A method for diagnosing cancer comprising detecting ROBO1 protein is disclosed. In addition, a method for treating a disease caused by abnormal cell growth comprising administrating an antibody that binds to ROBO1, as well as a pharmaceutical composition, a cell growth inhibitor and an anticancer agent comprising an antibody that binds to ROBO1 as an active ingredient are disclosed. Further, a method for inducing cell damages in a ROBO1 expressing cell and a method for inhibiting the growth of a ROBO1 expressing cell by bringing a ROBO1 expressing cell into contact with an antibody that binds to ROBO1, are disclosed. Furthermore, a method for monitoring progression of hepatitis by detecting ROBO1 protein is disclosed.
Abstract translation: 公开了一种诊断癌症的方法，包括检测ROBO1蛋白。 另外，用于治疗由异常细胞生长引起的疾病的方法包括施用与ROBO1结合的抗体，以及药物组合物，细胞生长抑制剂和抗癌剂，其包含结合ROBO1作为有效成分的抗体的方法， 披露 此外，公开了通过使ROBO1表达细胞与与ROBO1结合的抗体接触来抑制ROBO1表达细胞中的细胞损伤的方法和抑制ROBO1表达细胞的生长的方法。 此外，公开了通过检测ROBO1蛋白来监测肝炎进展的方法。
-
公开(公告)号：US07919086B2
公开(公告)日：2011-04-05
申请号：US10583795
申请日：2005-07-08
Applicant: Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
Inventor： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
CPC classification number: C07K16/28 , C07K7/06 , C07K14/47 , C07K16/303 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92
Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
Abstract translation: 公开了能够结合磷脂酰肌醇蛋白聚糖3的特定区域的抗体以及基于该抗体产生的人源化抗体。 本发明的抗GPC3抗体与常规抗体相比具有较高的ADCC活性和CDC活性。 本发明的抗体可用作细胞生长抑制剂，抗癌剂和癌症诊断剂。
-
公开(公告)号：US20080107654A1
公开(公告)日：2008-05-08
申请号：US10578840
申请日：2004-11-11
Applicant: Yasufumi Kikuchi , Shinsuke Uno , Yasuko Kinoshita , Shigeyuki Iijima , Naoshi Fukushima , Masayuki Tsuchiya
Inventor： Yasufumi Kikuchi , Shinsuke Uno , Yasuko Kinoshita , Shigeyuki Iijima , Naoshi Fukushima , Masayuki Tsuchiya
CPC classification number: C07K16/2803 , C07K2317/24 , C07K2317/50 , C07K2317/73
Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.
Abstract translation: 本发明涉及与CD47结合的人源化抗体; 结合人CD47的双抗体，其特征在于二糖键存在于形成双抗体的片段之间; 编码任何一种所述抗体的基因; 含有所述基因的载体; 含有所述载体的宿主细胞; 制备抗体的方法包括培养所述宿主细胞的步骤; 和包含所述抗体的血液病症治疗剂。
-
Patent Agency Ranking
公开(公告)号：US20070190599A1
公开(公告)日：2007-08-16
申请号：US10583795
申请日：2005-07-08
Applicant: Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
Inventor： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
CPC classification number: C07K16/28 , C07K7/06 , C07K14/47 , C07K16/303 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92
Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
Abstract translation: 公开了能够结合磷脂酰肌醇蛋白聚糖3的特定区域的抗体以及基于该抗体产生的人源化抗体。 本发明的抗GPC3抗体与常规抗体相比具有较高的ADCC活性和CDC活性。 本发明的抗体可用作细胞生长抑制剂，抗癌剂和癌症诊断剂。
-
公开(公告)号：US08759025B2
公开(公告)日：2014-06-24
申请号：US13329658
申请日：2011-12-19
Applicant: Yasufumi Kikuchi , Shinsuke Uno , Yasuko Kinoshita , Shigeyuki Iijima , Naoshi Fukushima , Masayuki Tsuchiya
Inventor： Yasufumi Kikuchi , Shinsuke Uno , Yasuko Kinoshita , Shigeyuki Iijima , Naoshi Fukushima , Masayuki Tsuchiya
CPC classification number: C07K16/2803 , C07K2317/24 , C07K2317/50 , C07K2317/73
Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.
Abstract translation: 本发明涉及与CD47结合的人源化抗体; 结合人CD47的双抗体，其特征在于二糖键存在于形成双抗体的片段之间; 编码任何一种所述抗体的基因; 含有所述基因的载体; 含有所述载体的宿主细胞; 制备抗体的方法包括培养所述宿主细胞的步骤; 和包含所述抗体的血液病症治疗剂。
-
公开(公告)号：US07871613B2
公开(公告)日：2011-01-18
申请号：US11574091
申请日：2005-08-23
Applicant: Yasuko Kinoshita , Masamichi Sugimoto , Hisafumi Okabe
Inventor： Yasuko Kinoshita , Masamichi Sugimoto , Hisafumi Okabe
IPC: A61K39/395 , A61K39/00 , C07K16/00 , C12P21/08
CPC classification number: C07K16/303 , A61K2039/505 , C07K2317/73
Abstract: The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.
Abstract translation: 本发明提供了包含抗磷脂酰肌醇蛋白聚糖3抗体的抗癌剂，其中抗癌剂在癌症治疗后施用，优选在癌症治疗后经肝癌治疗后，肝癌治疗为 特别是切除肝癌细胞。 如果在切除的肝癌细胞中表达磷脂酰肌醇蛋白聚糖3，则优选施用本发明的抗癌剂。 抗磷脂酰肌醇蛋白聚糖3抗体优选为单克隆抗体。 根据本发明的抗癌剂可用于预防癌症和预防癌症复发。
-
公开(公告)号：US07776329B2
公开(公告)日：2010-08-17
申请号：US10583795
申请日：2005-07-08
Applicant: Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
Inventor： Kiyotaka Nakano , Takeshi Yoshino , Jun-Ichi Nezu , Hiroyuki Tsunoda , Tomoyuki Igawa , Hiroko Konishi , Megumi Tanaka , Izumi Sugo , Shigeto Kawai , Takahiro Ishiguro , Yasuko Kinoshita
Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
-
公开(公告)号：US20110104157A1
公开(公告)日：2011-05-05
申请号：US12936367
申请日：2009-03-19
Applicant: Yasuko Kinoshita , Masamichi Sugimoto , Takahiro Ishiguro
Inventor： Yasuko Kinoshita , Masamichi Sugimoto , Takahiro Ishiguro
IPC: A61K39/395 , A61P35/00
CPC classification number: C07K16/303 , A61K31/404 , A61K31/44 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/565 , A61K2300/00
Abstract: A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.
Abstract translation: 提供了一种用于治疗或预防肝细胞癌的新型药物组合物和治疗方法。 通过将化学治疗剂与抗磷脂酰肌醇蛋白聚糖3抗体组合来获得用于治疗或预防肝癌的药物组合物。 还公开了用于治疗或预防肝癌的药物组合物，其包含与化疗剂组合使用的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，或者包含作为活性成分的化学治疗剂，其与抗 - - 糖蛋白3抗体。 使用化学治疗剂和抗磷脂酰肌醇蛋白聚糖3抗体组合产生比单独使用化学治疗剂更好的治疗效果，并减轻由化学治疗剂肝癌治疗产生的副作用。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.013 seconds)
